AACR 2025 at a glance
As AACR 2025 nears, LucidQuest spotlights the latest advances in cancer research, therapeutic development, and AI/ML-driven insights.
📅 Build your schedule around the topics that interest you.
📥 Download the AACR 2025_Preview_by_LucidQuest
Dive deeper
Key Topics From AACR 2025 Scientific Presentations
Immunotherapy
-
CAR-T vs blinatumomab both boost HSCT success in #B-ALL, delivering similar survival gains.
-
CIMLNK + tafasitamab doubles cytotoxicity over CAR-T in pre-clinical B-ALL.
-
Nurulimab + prolgolimab lifts PFS in metastatic melanoma, while OriC613 CAR-T (MSLN/CLDN18.2) shows potent activity in pancreatic & gastric cancers with zero GI toxicity. 🏹💉
Targeted Therapies
-
Claudin 18.2 IHC (PPA/NPA/OPA 100%) validates patient selection for zolbetuximab in gastric cancer.
-
Dual-warhead ADCs GQ1033 (EGFR × cMET) & GQ1030 (DLL3) drive strong responses in NSCLC/SCLC; LBL-054 (CDH17) and AZD9592 (EGFR × cMET) achieve deep tumor regression in GI cancers. 🎯🧬
Preclinical Insights
-
[161Tb]Tb-DOTA-N4MU01 radioligand targets Nectin-4+ TNBC/NSCLC.
-
AZD9750 (oral AR PROTAC) active in prostate PDX; Tumor Treating Fields + chemo synergize in SCLC. 🚀🔎
Clinical Trials
-
DRL_BZ phase IV confirms broad solid-tumor activity with a steady safety profile.
-
Rucaparib + nivolumab finds ctDNA predicts early LMS progression.
-
Castalagin (phase I) enhances ICI efficacy in NSCLC & melanoma. 🌐📈
Biomarkers
-
I/M score guides therapy in BTC & PDAC; KRAS-mut CRC co-mutations refine prognosis; ccDNA profiling stratifies EGFR-NSCLC. 🧪💡
Tumor Microenvironment
-
M0674 trispecific & disitamab vedotin overcome HER2-resistance; STING activation boosts doxorubicin in STS.
Misc Oncology
-
Trop-2 ISACs shrink pancreatic tumors; USP1 inhibitors show pan-cancer potency; Oncuria-Detect hits 90% sensitivity for bladder cancer.
Artificial Intelligence and Machine Learning at AACR 2025
AI for Risk
-
Ensemble model (AUC 0.99) predicts cardio-oncology mortality in Black patients. 🤖❤️
Subtype AI
-
Classifier: 86% sens / 95% spec maps SCLC subtypes to immune phenotypes. 🔎🗂️
Serial CTRS
-
Deep learning outperforms RECIST for 1-year OS in NSCLC (HR 2.68 high vs low responders).
Drug Discovery AI
-
DeepSynBa cuts RMSE 65% in drug-synergy prediction; TeloPred flags 10 lead telomerase inhibitors (87% accuracy). 💊✨
NeoVaccine AI
-
Optimized TP53 peptides heighten CD8⁺ T-cell activation for bespoke vaccines. 🎯🧫
Workflow Efficiency
-
“C the Signs” AI triage removed 61k unnecessary referrals during COVID, doubling diagnostic yield. 📈🏥
📅 Build your schedule around the topics that interest you.
📥 Download the AACR 2025_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.